IBDEI1X4 ; ; 04-FEB-2020
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,30637,1,4,0)
;;=4^I31.9
;;^UTILITY(U,$J,358.3,30637,2)
;;=^5007165
;;^UTILITY(U,$J,358.3,30638,0)
;;=I49.9^^123^1579^2
;;^UTILITY(U,$J,358.3,30638,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30638,1,3,0)
;;=3^Arrhythmia,Cardiac,Unspec
;;^UTILITY(U,$J,358.3,30638,1,4,0)
;;=4^I49.9
;;^UTILITY(U,$J,358.3,30638,2)
;;=^5007237
;;^UTILITY(U,$J,358.3,30639,0)
;;=I13.0^^123^1579^9
;;^UTILITY(U,$J,358.3,30639,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30639,1,3,0)
;;=3^HTN Hrt Disease w/ Hrt Failure and CKD,Stage 1-4
;;^UTILITY(U,$J,358.3,30639,1,4,0)
;;=4^I13.0
;;^UTILITY(U,$J,358.3,30639,2)
;;=^5007067
;;^UTILITY(U,$J,358.3,30640,0)
;;=I13.2^^123^1579^10
;;^UTILITY(U,$J,358.3,30640,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30640,1,3,0)
;;=3^HTN Hrt Disease w/ Hrt Failure and CKD, Stage 5 or ESRD
;;^UTILITY(U,$J,358.3,30640,1,4,0)
;;=4^I13.2
;;^UTILITY(U,$J,358.3,30640,2)
;;=^5007070
;;^UTILITY(U,$J,358.3,30641,0)
;;=I13.10^^123^1579^11
;;^UTILITY(U,$J,358.3,30641,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30641,1,3,0)
;;=3^HTN Hrt Disease w/o Hrt Failure and CKD, Stage 1-4
;;^UTILITY(U,$J,358.3,30641,1,4,0)
;;=4^I13.10
;;^UTILITY(U,$J,358.3,30641,2)
;;=^5007068
;;^UTILITY(U,$J,358.3,30642,0)
;;=I13.11^^123^1579^12
;;^UTILITY(U,$J,358.3,30642,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30642,1,3,0)
;;=3^HTN Hrt Disease w/o Hrt Failure and CKD,Stage 5 or ESRD
;;^UTILITY(U,$J,358.3,30642,1,4,0)
;;=4^I13.11
;;^UTILITY(U,$J,358.3,30642,2)
;;=^5007069
;;^UTILITY(U,$J,358.3,30643,0)
;;=I50.1^^123^1579^15
;;^UTILITY(U,$J,358.3,30643,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30643,1,3,0)
;;=3^Left Ventricular Failure
;;^UTILITY(U,$J,358.3,30643,1,4,0)
;;=4^I50.1
;;^UTILITY(U,$J,358.3,30643,2)
;;=^5007238
;;^UTILITY(U,$J,358.3,30644,0)
;;=E21.3^^123^1580^17
;;^UTILITY(U,$J,358.3,30644,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30644,1,3,0)
;;=3^Hyperparathyroidism,Unspec
;;^UTILITY(U,$J,358.3,30644,1,4,0)
;;=4^E21.3
;;^UTILITY(U,$J,358.3,30644,2)
;;=^331438
;;^UTILITY(U,$J,358.3,30645,0)
;;=E78.5^^123^1580^16
;;^UTILITY(U,$J,358.3,30645,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30645,1,3,0)
;;=3^Hyperlipidemia,Unspec
;;^UTILITY(U,$J,358.3,30645,1,4,0)
;;=4^E78.5
;;^UTILITY(U,$J,358.3,30645,2)
;;=^5002969
;;^UTILITY(U,$J,358.3,30646,0)
;;=M10.30^^123^1580^11
;;^UTILITY(U,$J,358.3,30646,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30646,1,3,0)
;;=3^Gout d/t Renal Impairment,Unspec Site
;;^UTILITY(U,$J,358.3,30646,1,4,0)
;;=4^M10.30
;;^UTILITY(U,$J,358.3,30646,2)
;;=^5010356
;;^UTILITY(U,$J,358.3,30647,0)
;;=E66.9^^123^1580^33
;;^UTILITY(U,$J,358.3,30647,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30647,1,3,0)
;;=3^Obesity,Unspec
;;^UTILITY(U,$J,358.3,30647,1,4,0)
;;=4^E66.9
;;^UTILITY(U,$J,358.3,30647,2)
;;=^5002832
;;^UTILITY(U,$J,358.3,30648,0)
;;=E66.01^^123^1580^32
;;^UTILITY(U,$J,358.3,30648,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30648,1,3,0)
;;=3^Obesity,Morbid,d/t Excess Calories
;;^UTILITY(U,$J,358.3,30648,1,4,0)
;;=4^E66.01
;;^UTILITY(U,$J,358.3,30648,2)
;;=^5002826
;;^UTILITY(U,$J,358.3,30649,0)
;;=D50.9^^123^1580^2
;;^UTILITY(U,$J,358.3,30649,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30649,1,3,0)
;;=3^Anemia,Iron Deficiency,Unspec
;;^UTILITY(U,$J,358.3,30649,1,4,0)
;;=4^D50.9
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI1X4 3764 printed Sep 23, 2025@19:53:31 Page 2
IBDEI1X4 ; ; 04-FEB-2020
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,30637,1,4,0)
+2 ;;=4^I31.9
+3 ;;^UTILITY(U,$J,358.3,30637,2)
+4 ;;=^5007165
+5 ;;^UTILITY(U,$J,358.3,30638,0)
+6 ;;=I49.9^^123^1579^2
+7 ;;^UTILITY(U,$J,358.3,30638,1,0)
+8 ;;=^358.31IA^4^2
+9 ;;^UTILITY(U,$J,358.3,30638,1,3,0)
+10 ;;=3^Arrhythmia,Cardiac,Unspec
+11 ;;^UTILITY(U,$J,358.3,30638,1,4,0)
+12 ;;=4^I49.9
+13 ;;^UTILITY(U,$J,358.3,30638,2)
+14 ;;=^5007237
+15 ;;^UTILITY(U,$J,358.3,30639,0)
+16 ;;=I13.0^^123^1579^9
+17 ;;^UTILITY(U,$J,358.3,30639,1,0)
+18 ;;=^358.31IA^4^2
+19 ;;^UTILITY(U,$J,358.3,30639,1,3,0)
+20 ;;=3^HTN Hrt Disease w/ Hrt Failure and CKD,Stage 1-4
+21 ;;^UTILITY(U,$J,358.3,30639,1,4,0)
+22 ;;=4^I13.0
+23 ;;^UTILITY(U,$J,358.3,30639,2)
+24 ;;=^5007067
+25 ;;^UTILITY(U,$J,358.3,30640,0)
+26 ;;=I13.2^^123^1579^10
+27 ;;^UTILITY(U,$J,358.3,30640,1,0)
+28 ;;=^358.31IA^4^2
+29 ;;^UTILITY(U,$J,358.3,30640,1,3,0)
+30 ;;=3^HTN Hrt Disease w/ Hrt Failure and CKD, Stage 5 or ESRD
+31 ;;^UTILITY(U,$J,358.3,30640,1,4,0)
+32 ;;=4^I13.2
+33 ;;^UTILITY(U,$J,358.3,30640,2)
+34 ;;=^5007070
+35 ;;^UTILITY(U,$J,358.3,30641,0)
+36 ;;=I13.10^^123^1579^11
+37 ;;^UTILITY(U,$J,358.3,30641,1,0)
+38 ;;=^358.31IA^4^2
+39 ;;^UTILITY(U,$J,358.3,30641,1,3,0)
+40 ;;=3^HTN Hrt Disease w/o Hrt Failure and CKD, Stage 1-4
+41 ;;^UTILITY(U,$J,358.3,30641,1,4,0)
+42 ;;=4^I13.10
+43 ;;^UTILITY(U,$J,358.3,30641,2)
+44 ;;=^5007068
+45 ;;^UTILITY(U,$J,358.3,30642,0)
+46 ;;=I13.11^^123^1579^12
+47 ;;^UTILITY(U,$J,358.3,30642,1,0)
+48 ;;=^358.31IA^4^2
+49 ;;^UTILITY(U,$J,358.3,30642,1,3,0)
+50 ;;=3^HTN Hrt Disease w/o Hrt Failure and CKD,Stage 5 or ESRD
+51 ;;^UTILITY(U,$J,358.3,30642,1,4,0)
+52 ;;=4^I13.11
+53 ;;^UTILITY(U,$J,358.3,30642,2)
+54 ;;=^5007069
+55 ;;^UTILITY(U,$J,358.3,30643,0)
+56 ;;=I50.1^^123^1579^15
+57 ;;^UTILITY(U,$J,358.3,30643,1,0)
+58 ;;=^358.31IA^4^2
+59 ;;^UTILITY(U,$J,358.3,30643,1,3,0)
+60 ;;=3^Left Ventricular Failure
+61 ;;^UTILITY(U,$J,358.3,30643,1,4,0)
+62 ;;=4^I50.1
+63 ;;^UTILITY(U,$J,358.3,30643,2)
+64 ;;=^5007238
+65 ;;^UTILITY(U,$J,358.3,30644,0)
+66 ;;=E21.3^^123^1580^17
+67 ;;^UTILITY(U,$J,358.3,30644,1,0)
+68 ;;=^358.31IA^4^2
+69 ;;^UTILITY(U,$J,358.3,30644,1,3,0)
+70 ;;=3^Hyperparathyroidism,Unspec
+71 ;;^UTILITY(U,$J,358.3,30644,1,4,0)
+72 ;;=4^E21.3
+73 ;;^UTILITY(U,$J,358.3,30644,2)
+74 ;;=^331438
+75 ;;^UTILITY(U,$J,358.3,30645,0)
+76 ;;=E78.5^^123^1580^16
+77 ;;^UTILITY(U,$J,358.3,30645,1,0)
+78 ;;=^358.31IA^4^2
+79 ;;^UTILITY(U,$J,358.3,30645,1,3,0)
+80 ;;=3^Hyperlipidemia,Unspec
+81 ;;^UTILITY(U,$J,358.3,30645,1,4,0)
+82 ;;=4^E78.5
+83 ;;^UTILITY(U,$J,358.3,30645,2)
+84 ;;=^5002969
+85 ;;^UTILITY(U,$J,358.3,30646,0)
+86 ;;=M10.30^^123^1580^11
+87 ;;^UTILITY(U,$J,358.3,30646,1,0)
+88 ;;=^358.31IA^4^2
+89 ;;^UTILITY(U,$J,358.3,30646,1,3,0)
+90 ;;=3^Gout d/t Renal Impairment,Unspec Site
+91 ;;^UTILITY(U,$J,358.3,30646,1,4,0)
+92 ;;=4^M10.30
+93 ;;^UTILITY(U,$J,358.3,30646,2)
+94 ;;=^5010356
+95 ;;^UTILITY(U,$J,358.3,30647,0)
+96 ;;=E66.9^^123^1580^33
+97 ;;^UTILITY(U,$J,358.3,30647,1,0)
+98 ;;=^358.31IA^4^2
+99 ;;^UTILITY(U,$J,358.3,30647,1,3,0)
+100 ;;=3^Obesity,Unspec
+101 ;;^UTILITY(U,$J,358.3,30647,1,4,0)
+102 ;;=4^E66.9
+103 ;;^UTILITY(U,$J,358.3,30647,2)
+104 ;;=^5002832
+105 ;;^UTILITY(U,$J,358.3,30648,0)
+106 ;;=E66.01^^123^1580^32
+107 ;;^UTILITY(U,$J,358.3,30648,1,0)
+108 ;;=^358.31IA^4^2
+109 ;;^UTILITY(U,$J,358.3,30648,1,3,0)
+110 ;;=3^Obesity,Morbid,d/t Excess Calories
+111 ;;^UTILITY(U,$J,358.3,30648,1,4,0)
+112 ;;=4^E66.01
+113 ;;^UTILITY(U,$J,358.3,30648,2)
+114 ;;=^5002826
+115 ;;^UTILITY(U,$J,358.3,30649,0)
+116 ;;=D50.9^^123^1580^2
+117 ;;^UTILITY(U,$J,358.3,30649,1,0)
+118 ;;=^358.31IA^4^2
+119 ;;^UTILITY(U,$J,358.3,30649,1,3,0)
+120 ;;=3^Anemia,Iron Deficiency,Unspec
+121 ;;^UTILITY(U,$J,358.3,30649,1,4,0)
+122 ;;=4^D50.9
